These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 18357638)

  • 1. Prasugrel versus clopidogrel.
    Pasceri V; Patti G; Di Sciascio G
    N Engl J Med; 2008 Mar; 358(12):1298-9; author reply 1299-301. PubMed ID: 18357638
    [No Abstract]   [Full Text] [Related]  

  • 2. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial.
    Wiviott SD; Braunwald E; McCabe CH; Horvath I; Keltai M; Herrman JP; Van de Werf F; Downey WE; Scirica BM; Murphy SA; Antman EM;
    Lancet; 2008 Apr; 371(9621):1353-63. PubMed ID: 18377975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prasugrel versus clopidogrel.
    Serebruany V
    N Engl J Med; 2008 Mar; 358(12):1298; author reply 1299-301. PubMed ID: 18354110
    [No Abstract]   [Full Text] [Related]  

  • 4. Toward a therapeutic window for antiplatelet therapy in the elderly.
    Gurbel PA; Ohman EM; Jeong YH; Tantry US
    Eur Heart J; 2012 May; 33(10):1187-9. PubMed ID: 22270540
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]).
    Damman P; Varenhorst C; Koul S; Eriksson P; Erlinge D; Lagerqvist B; James SK
    Am J Cardiol; 2014 Jan; 113(1):64-9. PubMed ID: 24169009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching from prasugrel to clopidogrel: navigating in unknown waters.
    Angiolillo DJ; Rollini F
    JACC Cardiovasc Interv; 2013 Feb; 6(2):166-8. PubMed ID: 23428008
    [No Abstract]   [Full Text] [Related]  

  • 7. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
    Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to antiplatelet treatment: from genes to outcome.
    Giusti B; Abbate R
    Lancet; 2010 Oct; 376(9749):1278-81. PubMed ID: 20801497
    [No Abstract]   [Full Text] [Related]  

  • 9. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
    Aradi D; Tornyos A; Pintér T; Vorobcsuk A; Kónyi A; Faluközy J; Veress G; Magyari B; Horváth IG; Komócsi A
    J Am Coll Cardiol; 2014 Mar; 63(11):1061-70. PubMed ID: 24486281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prasugrel for the treatment of patients with acute coronary syndrome.
    Marzot F; Pengo V
    Vasc Health Risk Manag; 2009; 5(1):321-4. PubMed ID: 19436677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis.
    Smith PK; Goodnough LT; Levy JH; Poston RS; Short MA; Weerakkody GJ; Lenarz LA
    J Am Coll Cardiol; 2012 Jul; 60(5):388-96. PubMed ID: 22633653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A potent alternative to clopidogrel emerges. Prasugrel appears to lower heart attack risk for patients with acute coronary syndrome.
    Heart Advis; 2010 May; 13(5):6. PubMed ID: 22816152
    [No Abstract]   [Full Text] [Related]  

  • 13. High on-treatment platelet reactivity (HPR): what does it mean, and does it matter?
    Goto S; Tomiya A
    Thromb Haemost; 2013 Feb; 109(2):177-8. PubMed ID: 23306954
    [No Abstract]   [Full Text] [Related]  

  • 14. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
    Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E
    J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prasugrel versus clopidogrel.
    von Lewinski F; Riggert J; Paulus W
    N Engl J Med; 2008 Mar; 358(12):1299; author reply 1299-301. PubMed ID: 18357639
    [No Abstract]   [Full Text] [Related]  

  • 16. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
    O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
    J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Letter by Serebruany regarding article, "Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38".
    Serebruany VL
    Circulation; 2010 Aug; 122(8):e436; author reply e437. PubMed ID: 20733108
    [No Abstract]   [Full Text] [Related]  

  • 18. Is prasugrel more effective than clopidogrel in patients with acute coronary syndrome scheduled for PCI?
    Graber MA; Dachs R; Darby-Stewart A
    Am Fam Physician; 2008 Dec; 78(11):1252-3. PubMed ID: 19069017
    [No Abstract]   [Full Text] [Related]  

  • 19. Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial.
    Diodati JG; Saucedo JF; Cardillo TE; Jakubowski JA; Henneges C; Effron MB; Lipkin FR; Walker JR; Duvvuru S; Sundseth SS; Fisher HN; Angiolillo DJ
    Thromb Haemost; 2014 Aug; 112(2):311-22. PubMed ID: 24718367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
    Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
    J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.